Clinical Stage CAR-T for AL Amyloidosis and Select Immune-Mediated Diseases

RECENT NEWS

IMMIX BIOPHARMA

Prioritizing Patient wellbeing

Prioritizing patient well-being with innovative treatments that simplify and enhance the recovery process.

Voices of Hope: Real Stories from AL Amyloidosis Warriors

Discover the transformative journeys of individuals who have bravely navigated their treatment with our groundbreaking therapy. Hear firsthand how their lives have been changed and their futures reimagined.

Learn More

Support groundbreaking advancements in healthcare

Seize the opportunity to support groundbreaking advancements in healthcare that promise both significant patient impact and strong investment potential.

AL Amyloidoisis And Immune-mediated Disease CAR-T Clinical Trailblazer

Immix Biopharma (NASDAQ : IMMX) is a leader in pioneering AL Amyloidosis and immune-mediated disease CAR-T therapies. Our strategic approach to innovation and market potential positions us as a prime candidate for investors seeking to impact the healthcare landscape and achieve substantial returns.

Learn More

Cutting-edge research and transformative technologies

Driving the next wave of medical breakthroughs with cutting-edge research and transformative technologies in AL Amyloidosis and select immune-mediated disease therapy.

IMMIXBIO N-GENIUS sterically-optimized Cell Therapy Platform

Our N-GENIUS platform, with EXPAND technology, has produced our pioneering lead candidate, CAR-T NXC-201, which has demonstrated an enhanced tolerability profile with the potential to reduce hospitalizations.

Learn More

CAR-T Clinical Trailblazer in AL Amyloidosis and immune-mediated diseases

Leading the charge AL Amyloidosis and select immune-mediated disease care as trailblazers of innovative CAR-T therapies, reshaping treatment landscapes and patient outcomes.

Hear from the Team

Meet our team of innovators and thinkers at Immix Biopharma, whose dedication and expertise are paving the way for revolutionary treatments in AL Amyloidosis and immune-mediated diseases. Hear their insights and learn about the passion that drives our mission forward.

Learn More

CAR-T THERAPY

Despite impressive research and development progress in CAR-T cell therapies, today 95% of U.S. medical centers are unable to dose CAR-T cell therapies due to neurotoxicity, and only a narrow band of patients in specific indications are able to benefit from CAR-Ts.

“Today, CAR-T cell therapies generate greater than $3 billion of annualized sales, even though due to neurotoxicity and side effects, they are dosed in only 5% of U.S. hospitals. NXC-201 has been dosed in a large number of patients across released/refractory AL amyloidosis and relapsed/refractory multiple myeloma. We believe NXC-201 could offer hope to those on waiting lists for CAR-T cell therapies, and potentially become the first out-patient CAR-T expanding into to the remaining 95% of U.S. hospitals.”

IMPACTING AL AMYLOIDOSIS AND select immune-mediated diseases

At ImmixBio, we are aiming to become the first company to overcome the greatest obstacle to CAR-T adoption: neurotoxicity. By overcoming neurotoxicity, we aim to expand into select immune-mediated diseases that were not possible in the past (starting with AL Amyloidosis), and places not possible in the past (the 95% of U.S. medical centers today that are unable to dose CAR-T therapies).

INDUSTRY LEADING PARTNERS

Immix Biopharma collaborates with top-tier industry leaders to accelerate our research and development efforts. Together, we are committed to advancing groundbreaking therapies that promise to transform patient outcomes in AL Amyloidosis and select immune-mediated diseases.

BE A PART OF THE FUTURE OF HEALTHCARE

Subscribe to our newsletter for exclusive updates on pioneering medical breakthroughs, the newest research developments, and innovative treatments. Stay connected and play a role in shaping the future of healthcare. Register now!